Ultime notizie per Imunon (NASDAQ:IMNN) Azioni

IMUNON INC

Imunon

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Imunon Inc

News

VMAR

Vision Marine's E-Motion 180E Approved Under California CORE, Unlocks Up To $170K Vouchers Per Vessel

Compass Point analyst Casey Alexander initiates coverage on Blue Owl Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTF#NYSE">OTF</a>) with a Buy rating and announces Price Target of $17.

Price Target

Initiation

Analyst Ratings

Compass Point Initiates Coverage On Blue Owl Technology with Buy Rating, Announces Price Target of $17

<ul>
<li>TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month1</li>
<li>Atogepant met the primary endpoint of fewer treatment discontinuations attributed to adverse events versus topiramate, and all six secondary endpoints achieved statistical significance for superiority versus topiramate, demonstrating clinical efficacy1</li>
<li>Full results from the TEMPLE study will be presented at an upcoming medical meeting</li>
</ul>

Biotech

Large Cap

Health Care

General

ABBV

AbbVie Announced Topline Results From Its Phase 3 TEMPLE Trial Of Atogepant Compared To The Highest Tolerated Dose Of Topiramate In Migraine Patients, The Study Met The Primary Endpoint

Small Cap Consumer Research analyst Eric Beder reiterates Vince Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) with a Buy and maintains $4 price target.

Reiteration

VNCE

Small Cap Consumer Research Reiterates Buy on Vince Holding, Maintains $4 Price Target

Aurora Cannabis (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ACB#TSX">ACB</a>) reported quarterly losses of $(0.35) per share. This is a 14.63 percent increase over losses of $(0.41) per share from the same period last year. The company reported $90.54 million in sales this quarter. This is a 34.31 percent increase over sales of $67.41 million the same period last year.

Earnings

TSX:ACB

Aurora Cannabis Q4 EPS $(0.35) Up From $(0.41) YoY, Sales $90.54M Up From $67.41M YoY

Needham analyst Quinn Bolton reiterates Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Buy and maintains $85 price target.

MRVL

Needham Reiterates Buy on Marvell Tech, Maintains $85 Price Target

WIIM

SRRK

Scholar Rock shares are trading higher after a study showed its new drug combination preserves muscle during tirzepatide-induced weight loss.

STSS

Sharps Technology shares are trading higher after initiating the second shipment of its first commercial order of SoloGard syringes under a multi-year supply agreement with a US-based IV flushing solutions provider.

Rosenblatt analyst Catharine Trebnick maintains NICE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) with a Buy and maintains $190 price target.

NICE

Rosenblatt Maintains Buy on NICE, Maintains $190 Price Target

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROIV#NASDAQ">ROIV</a>) with a Buy and maintains $18 price target.

ROIV

HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $18 Price Target

BDRX

Biodexa shares are trading higher after the company enrolled the first patient in its Phase 2a study of Tolimidone.

Vodafone Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOD#NASDAQ">VOD</a>) Vi (Vodafone Idea) and AST SpaceMobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) announced a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45991304/vi-and-ast-spacemobile-announce-partnership-for-satellite-connectivity" rel="noreferrer noopener">strategic partnership on</a> Wednesday to expand mobile connectivity across India&#8217;s unconnected regions.
This collaboration will leverage AST SpaceMobile&#8217;s groundbreaking technology, which recently demonstrated successful voice and video calls from space using a standard mobile phone.
While India boasts over 1.1 billion mobile subscribers and extensive 4G and emerging 5G networks, satellite communication will prove crucial in expanding broadband cellular access to challenging terrains.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/space/25/04/45046112/ast-spacemobile-partners-with-us-science-foundation-to-protect-astronomy-observations-while-expanding-satellite-network" rel="noreferrer noopener">AST SpaceMobile Partners With US Science Foundation To Protect Astronomy Observations While Expanding Satellite Network</a>
This partnership will combine Vi&#8217;s national network with AST SpaceMobile&#8217;s revolutionary space-based cellular technology. This technology connects directly to smartphones without specialized software, device support, or updates.
Aligned with Digital India&#8217;s initiatives, AST SpaceMobile and Vodafone Idea will collaborate on the SpaceMobile Satellite System.
The space-based cellular broadband ecosystem will be designed to expand Vi&#8217;s terrestrial connectivity telecom services, providing voice, video, data streaming, and internet access.
It will encompass the design, implementation, and launch of this system, wherein AST SpaceMobile will develop, manufacture, and manage the satellite constellation, and Vi will oversee terrestrial network integration, operating spectrum, and market access.
This announcement comes on the heels of other significant developments in India&#8217;s satellite internet landscape, including Elon Musk&#8217;s SpaceX <a target="_blank" href="https://www.benzinga.com/general/space/25/03/44244377/elon-musks-spacex-partners-with-airtel-to-launch-starlink-in-india-weeks-after-pm-narendra-modis-us-visit" rel="noreferrer noopener">partnering with Indian telecom company</a> Bharti Airtel in March to offer Starlink satellite internet services.
India&#8217;s Department of Telecommunications had requested&nbsp;security assurances&nbsp;from satellite communication providers like Starlink and Amazon.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>).
Starlink and Amazon&#8217;s Project Kuiper&nbsp;have also advocated for reduced spectrum charges and long-term licenses to make satellite services more affordable for Indian consumers.
ASTS&nbsp;Price Action: ASTS stock is trading higher by 3.39% to $41.46 premarket at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/24/12/42536024/taiwan-eyes-amazons-kuiper-as-starlink-faces-hurdles" target="_blank" rel="noreferrer noopener">Amazon&#8217;s Project Kuiper In Talks With Taiwan For Satellite Partnership</a></li>
</ul>
Photo via Shutterstock

Asia

Movers

Tech

AMZN

ASTS

Vodafone, AST SpaceMobile Partner To Bring Satellite Phone Service To Remote Parts Of India

LITM

Snow Lake Completes 2,719 Meters Of RC Drilling At Engo Valley With 8 Of 31 Holes Returning Significant Uranium Mineralization

Rosenblatt analyst Kevin Cassidy maintains Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Buy and maintains $124 price target.

Rosenblatt Maintains Buy on Marvell Tech, Maintains $124 Price Target

AXSM

Axsome Says It Will Present SYMBRAVO Migraine Treatment Data From Multiple Trials At AHS 2025 Annual Meeting

President Donald Trump met with Canadian Prime Minister Mark Carney on the sidelines of the G7 summit in Kananaskis, Alberta, on Monday. The media anticipated the conversation to clarify the tense U.S.-Canada relations, which have been strained over tariff escalations and a repeated proposal to <a target="_blank" href="https://www.benzinga.com/25/02/43582659/trump-says-canada-much-better-off-being-the-51st-state-the-border-with-us-is-just-a-line" rel="noreferrer noopener">annex the country as the 51st state</a>.
However, Carney's election in April promised to rebuild a more equal partnership between Ottawa and Washington, shifting the narrative to one of a more pragmatic nature.
"I'm a tariff person," Trump said in a <a target="_blank" href="https://www.youtube.com/watch?v=azGiHYbeiTU" rel="noreferrer noopener">video</a> posted by the Associated Press, explaining his stance on trade.&nbsp;"It's simple, it's easy, it's precise," he added, noting that Carney had "a different concept" but that they would explore both approaches.
Despite their differing philosophies, Trump confirmed a deal was "achievable" within weeks, hinting at openness to negotiation.
Josh Lipsky of the Atlantic Council's GeoEconomics Center reflected on the cautiously optimistic meeting.
"Is it tense? Yes. Is it awkward? Yes. The vibe would be best described as, ‘Let's just get through this.' Everyone is there, and everyone doesn't want a major dust-up," he said <a target="_blank" href="https://www.nytimes.com/2025/06/16/world/canada/canada-g7-trump-carney.html" rel="noreferrer noopener">per</a> the NY Times.
Journalists pressed Trump on key issues, including what was preventing a trade deal. Trump noted active talks between the two parties before turning to criticize former President Barack Obama and former Canadian Prime Minister Justin Trudeau for their role in removing Russia from (what was once) the G8.
"That was a big mistake," Trump said. "You wouldn't have a war right now if Russia had been at the table. If I were president four years ago, you wouldn't have this war."
He also responded to a question about China's inclusion in the G7, calling it "not a bad idea," but clarified that one needs partners with whom they can discuss matters.
The biggest elephant in the room was probably the ongoing conflict between Israel and Iran. When asked about potential U.S. military involvement, he refused to comment.
However, he noted that there was further action to be taken. "They (Iran) want to make a deal …And as soon as I leave here, we're going to be doing something. But I have to leave here," suggesting imminent developments.
Trump and Carney agreed to pursue further negotiations and a potential deal over the next 30 days before Trump cut the visit short and returned to Washington.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/06/45972264/senate-advances-stablecoin-bill-a-defining-moment-for-crypto-market-regulation" target="_blank" rel="noreferrer noopener">Senate Advances Stablecoin Bill: A Defining Moment For Crypto Market Regulation</a></li>
</ul>
Photo courtesy: Shutterstock

Politics

Media

BBCA

FLCA

ITOT

Trump Cuts G7 Visit Short, Calls Canada Deal 'Achievable'

HC Wainwright &amp; Co. analyst Heiko Ihle maintains Western Copper &amp; Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/WRN#AMEX">WRN</a>) with a Buy and lowers the price target from $4.25 to $4.

HC Wainwright & Co. Maintains Buy on Western Copper & Gold, Lowers Price Target to $4

New offering delivers convenient, comprehensive lab testing solutions for functional medicine, integrative medicine and primary care providers
BURLINGTON, N.C., June 18, 2025 /PRNewswire/ -- Labcorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), a global leader of innovative and comprehensive laboratory services, announced today the launch of <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4451797-1&amp;h=670611564&amp;u=https%3A%2F%2Fwww.labcorp.com%2Fproviders%2Fwhole-health-solutions&amp;a=Labcorp+Whole+Health+Solutions">Labcorp Whole Health Solutions</a>&nbsp;to support the growing needs of functional medicine, integrative medicine and primary care providers in delivering holistic care. The solution launches specialized test panels and a tailored test menu of more than 1,000 scientifically backed biomarkers for cardiometabolic health, hormones, micronutrients, longevity and whole body wellness.

Laboratory Corporation Of America Holdings

Labcorp Launches Labcorp Whole Health Solutions To Expand Holistic Care Offerings

INGR

Univar Solutions Expands Ingredion Partnership To Distribute Food Ingredients Across Benelux Region

Scholar Rock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and additional severe and debilitating neuromuscular diseases, today announced positive results from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-induced weight loss. The trial demonstrated that 30% of total weight loss with tirzepatide alone was due to lean mass loss. Apitegromab therapy (10 mg/kg) with tirzepatide preserved an additional 4.2 pounds (1.9 kilograms) or 54.9% (p=0.001) of lean mass compared to tirzepatide alone, leading to higher quality weight loss. Apitegromab with tirzepatide was generally well tolerated by participants.
"GLP therapies have been an effective and important innovation for individuals living with obesity and cardiometabolic disorders; however, these treatments can result in substantial loss of lean muscle mass for patients, leading to unwanted health risks," said Akshay Vaishnaw, M.D., Ph.D., President of R&amp;D, Scholar Rock. "We are pleased that the EMBRAZE trial accomplished its objective by achieving its primary endpoint. The results validated our hypothesis that our platform of highly selective myostatin inhibitors has the potential to support healthier weight loss for millions of patients on GLP therapies by safely preserving lean mass."
Dr. Vaishnaw added, "While this is an exciting development for our platform, we remain focused on preparing for the launch of apitegromab, and following its potential approval in SMA, we look forward to studying it in a range of neuromuscular diseases with high unmet need. Further, there is great potential with SRK-439 to be a subcutaneous, anti-myostatin antibody and we look forward to also exploring its potential in various rare, severe debilitating neuromuscular disorders. We remain on track to file an IND application for SRK-439 in the second half of this year to support the first in human study."
The EMBRAZE trial was designed to assess the ability to preserve lean body mass associated with tirzepatide-induced weight loss in patients with obesity (BMI of ≥30.0 kg/m2) or overweight (BMI≥27.0 kg/m2 with one or more weight-related co-morbidities). Treatment was administered over a 24-week period, and patients were randomized into two treatment arms: apitegromab with tirzepatide and placebo with tirzepatide.
Topline results successfully demonstrated proof-of-concept for a highly selective, anti-myostatin antibody to preserve lean mass, thus improving quality of weight loss with tirzepatide therapy.

Scholar Rock Study Shows New Drug Combo Preserves Muscle During Tirzepatide Weight Loss

Press Releases

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025

IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

IMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12th

Life Sciences Investor Forum Agenda Announced for June 11th-12th

Small-Cap Disruptors KZIA, SNYR, HSDT, TRNR, PRSO Lead Momentum – More Microcap Stocks Inside

Life Sciences Investor Forum: Now Available for Online Viewing

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

Comments

Imunon

Notizie

Ultime notizie per Imunon (NASDAQ:IMNN) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO